

Antimicrobial Activity of Probiotic Lactobacilli against some Pathogenic Bacteria

Radwan Rushdi (✉ razwanrushdi@gmail.com)

<https://orcid.org/0000-0002-2396-6743>

Maryam Rushdi

Research Article

Keywords: Antimicrobial activity, Lactobacilli, Probiotics, Pathogens

Posted Date: June 28th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1772979/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Probiotics are viable lactic acid bacteria (LAB) that are believed to provide health benefits when administered in appropriate quantities. Lactobacillus is one of the most important genera of LAB that are known to produce substances including bacteriocins which can inhibit the growth of pathogenic bacteria. The current study determined the antibacterial activity of probiotic lactobacilli against some clinical bacterial isolates. A commercially available probiotic lactobacilli product which contains (*Lactobacillus acidophilus* and *Lactobacillus Plantarum*) strains were tested for their antibacterial activity against the clinical bacterial isolates: *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*, following disk diffusion method. The cell-free supernatant of Lactobacilli strains isolated in the present study exhibited very remarkable and noticeable antimicrobial activity against pathogenic bacteria.

Introduction

Throughout the history of microbiology, most human studies have been focused on the disease-causing organisms found on or in people; whilst fewer studies have examined the benefits of the bacteria. However, we are surrounded by beneficial microorganisms that live in or on the human body. Probiotics are defined as live microorganisms when administered in adequate amounts confer a health benefit on the host¹⁻². Lactic acid bacteria (LAB) are considered as [Generally Recognized as Safe (GRAS)] organisms and can be safely used as probiotics for medical applications³. Members of the genus *Lactobacillus* are the most common probiotics used in commercial fermented and non-fermented products, such as in some yogurts and fermented milk drinks, as well as dietary supplements, which are available in the market in the form of capsules, liquid/gel, and powdered, to combat the diseases due to their ability to inhibit the pathogenic microorganisms⁴. Lactobacilli, primarily facultative or strict anaerobes generally have fastidious growth requirements. They prefer an acidic environment by producing lactic and other acids. In general, Lactobacilli have not been associated with disease and have been regarded as non-pathogenic and isolates were able to tolerate the acidic condition of the environment, NaCl concentration, and resistance to bile. The reported health benefits of probiotics include: boosting of the immune system, inhibition of the growth of pathogenic organisms, prevention of diarrhea from various causes, improvement of digestion of proteins and fats and synthesis of vitamins⁵. This study was conducted to detect the antimicrobial activity of the probiotic lactobacilli isolated from a commercial probiotic product against some bacterial pathogens. Probiotics, a word derived from Latin, that means 'for life', have been with us for as long as people have eaten fermented milk, but their association with health benefits dates only from the turn of the last century. Growing awareness of the health benefits of consuming microorganisms such as probiotics have encouraged consumers worldwide. These probiotic bacteria are essential for their beneficial effect on a particular organism's health and host nutrition for healthy gastrointestinal function. The original modern hypothesis of the

positive role played by certain bacteria was first introduced by Russian scientist Élie Metchnikoff, who in 1907 suggested that it would be possible to modify the gut microbiota and replace harmful microbes with useful microbes⁶. On the other hand, the rise in antibiotic-resistant has awakened the scientific community to the prophylactic and therapeutic uses of probiotics and to reconsider them as alternatives to antibiotics⁷. Over the last years, there has been increasing public and scientific interest in the administration of these live micro-organisms to prevent or treat disease. Twenty-three publications were retrieved from PubMed for the year 1995 using the search term 'probiotic' compared with about 200 in the year 2000 and more than 600 for the first half of 2012. Much of the focus of this research has been on the use of probiotics for the prevention or treatment of gastrointestinal conditions such as inflammatory bowel disease and inflammatory bowel syndrome⁸. Antimicrobial activity of *Lactobacillus* strains against bacterial pathogens emerges to be multifactorial and includes the production of hydrogen peroxide, lactic acid, bacteriocin-like molecules, and unknown heat-stable, non-lactic acid molecules⁹. Other mechanisms proposed for their activity are competition for nutrients¹⁰⁻¹¹, adhesion inhibition of pathogens to the surface, and stimulation of the immune system¹². One of the important features of probiotic lactobacilli to achieve antagonistic activity against bacterial pathogens because of their capacity to produce lactic acid and other organic acids that lower the pH in the human intestine, and to produce H₂O₂ and bacteriocin, thereby establishing a hospital environment for the growth and survival of various human pathogenic bacteria. There are also other physiological benefits of probiotics that have been published as it helps in the removal of carcinogens, lowering of cholesterol, immune-stimulating and allergy lowering effect, synthesis and enhancing the bioavailability of nutrients, alleviation of lactose intolerance¹³. One important limitation is that only one kind of probiotic bacteria may not exert protection against all harmful strains that cause gastrointestinal pathogenic infections¹⁴.

Materials And Methods

Isolation of probiotic strains

Commercial Probiotic product 'Vitalactic B' was used to isolate the probiotic lactobacilli used in the study. According to the product content information given on the " Vitalactic B " packet, two probiotic strains, *Lactobacillus plantarum*, and *Lactobacillus acidophilus* were present in it. " Vitalactic B " is in form of a capsule so the powder from the capsule were suspended in Brain Heart Infusion Broth (BHIB) and kept in aerobic and anaerobic conditions at 37°C for 24 hrs. The probiotic lactobacilli were subjected to cultural and morphological characterization. Then, the whole broth was centrifuged at 3000 rpm for 10 minutes and the was-free supernatant was collected and tested for its antibacterial activity against the clinical bacterial isolates.

Bacterial cultures and growth conditions

Clinical isolates of *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* with their case profiles were obtained from the laboratory of Nanakali hospital, Erbil, and maintained in brain heart infusion (BHI) agar and MacConkey agar. 2-3 isolated colonies of each

bacterial pathogen were sub-cultured onto (BHI) broth under aerobic conditions for 24 hours before testing. These bacteria served as test pathogens for antibacterial activity assay.

Detection of antimicrobial activity

The antimicrobial activity of probiotic lactobacilli from a commercial probiotic product was investigated against *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* using the method. For the purpose of production of paper discs, Whatman filter paper No.3 was used. Using an ordinary office hole punching machine, holes of approximately 6mm diameter were punched. The discs were then autoclaved at 15lbs pressure for 20 minutes¹⁵. Susceptibility of the pathogens to 2 antibiotics including gentamycin (GEN) and ampicillin (AMP) was also determined by the diffusion method. The Muller-Hinton agar plates were examined for the presence of inhibition zones around the paper disks. The result was considered positive when a clear zone around the paper disk was present whereas, negative was defined as the absence of a growth inhibition zone around the disk. Zones of inhibition were measured after incubation at 37°C for 24 hours and the results were recorded.

Results

Isolation and identification of *Lactobacillus* spp.

Probiotic lactobacilli were isolated from the commercial probiotic product " Vitalactic B " and identified by noticing their colony morphology (Fig. 1-A), and cultural as well as biochemical characteristics. Microscopically they were Gram-positive (Fig. 1-B), rod-shaped-motile, and absence of Endospore.

Antimicrobial activity

Lactobacilli strains were tested for their antimicrobial activity against some pathogenic bacteria by the disk diffusion method. The results revealed that the cell-free supernatant of *Lactobacillus Plantarum* and *Lactobacillus acidophilus*, in combination, exhibited the average inhibition (15–35 mm) on the growth of test pathogens: *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*, but had no activity against *Klebsiella pneumoniae*. On the other hand, all the test pathogens were resistant to ampicillin (AMP) and varies in their susceptibility to gentamycin (GEN). (Fig. 2) and (Table 1).

Discussion

It is a long time since scientists are trying to formulate alternative therapeutic protocols with non-antibiotic agents against bacterial infection. Nowadays, various natural products and methods are used to prevent or treat diseases. The use of probiotics is one of these methods. Lactobacilli are normal intestinal flora that plays an important role in human health. Probiotic Lactobacilli produce antimicrobial compounds such as bacteriocin, which can be used to prevent the growth of many bacteria. In this study, it was found that the cell-free supernatant of these bacteria, was able to inhibit the growth of *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*, the latter was in the highest

inhibitory effect, which comes in compatible with a study by¹⁶ which study the inhibitory activity of bacteriocin producing lactic acid bacteria (LAB) against *P. aeruginosa* and *Escherichia coli* using free cell supernatant and disk diffusion method. Jamalifar et.al.¹⁷ showed that *Lactobacillus acidophilus* exhibit significant inhibitory activity against clinical isolates of *P. aeruginosa* by different mechanisms. Similarly, a bacteriocin from *Plantarum* was found to be active against pathogenic bacteria including *Cl. Sporogeneses*, *E. faecalis*, *E. coli*, and *S. aureus*¹⁸⁻¹⁹. Antibacterial activity of bacteriocin produced by isolated probiotics showed that *Plantarum* has d strong antibacterial effect against enteric bacterial pathogens²⁰.

Table 1

Antibacterial activity of probiotic *Lactobacillus* strains supernatant compared with AMP and GEN in terms of zone of inhibition using the agar disk diffusion method.

Pathogenic Bacteria	Source	Zone of inhibition			
		probiotic <i>Lactobacillus</i> strains supernatant	AMP	GEN	Control
<i>Escherichia coli</i>	Stool	+ (15mm)	-	+ (20mm)	-
<i>Klebsiella pneumoniae</i>	Urine	-	-	+ (30mm)	-
<i>Pseudomonas aeruginosa</i>	Wound	+ (35mm)	-	-	-
<i>Staphylococcus aureus</i>	Urine	+ (20mm)	-	-	-

In our study, the cell-free supernatant of *Lactobacillus Plantarum* and *Lactobacillus acidophilus*, have no antimicrobial effect against *Klebsiella pneumoniae*. According to previous studies, a large number of lactic acid bacteria strains showed different bioactive potentials, especially in the form of antibacterial properties. The spectrum of antimicrobial activity for the species suggested that the inhibitory components were different²¹. Similarly, Hami,²² and Hassan Ali Maarof et.al.²³ observed varying degrees of inhibition of various pathogens by the culture filtrate of lactic acid bacteria, although these inhibitory substances produced by the lactic acid bacteria strains, they act differently on the pathogenic reference indicator strains. On the other hand, The inhibitory activity of probiotic *Lactobacillus* supernatant was compared with the inhibitory activity of AMP and GEN against the clinical pathogens. None of the antimicrobial agents was effective against all the tested pathogens demonstrating the current problem in the treatment of multi-drug resistant bacteria. In a previous study, *P. aeruginosa* isolates showed intermediate or full resistance to antimicrobial agents³. Unfortunately, *P. aeruginosa* and *S. aureus* showed complete resistance against gentamicin and ampicillin (AMP) and varies in their susceptibility to gentamycin (GEN). (Fig. 2) and (Table 1).

Conclusions

The results of the present study revealed the following:

1. The probiotic bacteria isolated in our study possess varying degrees of inhibition towards tested pathogenic bacteria.
2. Lactobacilli strains are potentially promising because they generate bactericidal bioactive agents that can control the growth of pathogens.
3. Results from our present study are expected to encourage people to consume probiotic products.
4. Given the increasing use of probiotics as health supplements and therapeutic agents, clinicians need to be aware of the risks and benefits. Although probiotics have an excellent overall safety record, they should be used with caution in certain patient groups particularly neonates born, prematurely or with immune deficiency.
5. Further, studies are needed to explore probiotic interactions.
6. Additional research data are needed to confirm a number of the health benefits in humans.

Declarations

Acknowledgments

This paper and the research behind it would not have been possible without the exceptional support of our supervisor, Sanaria Fawzi Jarjes. Her enthusiasm, knowledge, and exacting attention to detail have been an inspiration and kept us fully supported.

Conflict of Interest: The authors declare no conflict of interest.

References

1. Food and Agriculture Organization of the United Nations/World Health Organization FAO/WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic [Internet]; 2001. Available from: http://www.who.int/food_safety/publications/fs_management/en/probiotics.pdf [Accessed: 11.1.2016]
2. Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the Evaluation of Probiotics in Food; Joint FAO/WHO. London, Ontario, Canada: Food and Agriculture Organization of the United Nations/World Health Organization FAO/WHO; 2002.
3. Sieladie, DV; Zambou, NF; Kaktcham, PM; Cresci, A. and Fonteh, F (2011) Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of Cameroon. *Innovative Romanian Food Biotechnology* 9: 12–28.
4. Sonomoto, K. and A. Yokota (2011): *Lactic Acid Bacteria and Bifidobacteria: Current Progress in Advanced Research*. Caister Academic Press. ISBN 978-1-904455-82-0.
5. Prabhurajeshwar, Ch. and Chandrakanth, R.K. (2017). Probiotic potential of Lactobacilli with antagonistic activity against pathogenic strains: An in vitro validation for the production of inhibitory

- substances. *Biomed J.* 40(5): 270–283
6. Élie [Ilya Ilyich] Metchnikoff, 2004 [1907], *The prolongation of life: Optimistic studies*, p. 116. Springer Classics in Longevity and Aging, New York, NY: Springer, ISBN 0826118771, reprint of 1908 English edition by É.M., same title (P. Chalmers Mitchell, Ed.), New York, NY: Putnam, ISBN 0826118763, itself a translation of 1907 French edition by I.I.M., *Essais optimistic*, Paris: Heinemann, Retrieved 12 November 2015.
 7. Ahmed, F.E. (2003): Genetically modified probiotics in foods. *Trends Biotechnol.*, 21: 491–497.
 8. Fijan S. (2016). Antimicrobial Effect of Probiotics against Common Pathogens. Available from: <http://dx.doi.org/10.5772/63141>.
 9. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. *FEMS Microbiol Rev.* 2004;28:405–440.
 10. Mcfarland LV. Normal flora: diversity and functions. *Microb Ecol Health Dis.* 2000;12:193–207.
 11. Reid G, Burton J. Use of lactobacillus to prevent Infection by pathogenic bacteria. *Microbes Infection.* 2002;4:319–24.
 12. Gill H.S, Rutherford K.J, Cross M.L, Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic *Bifidobacterium lactis* HN019. *Am J Clin Nutr.* 2001;74:833–839.
 13. Ouwehand A.C, Salminen S, and I. E., Probiotics: an overview of beneficial effects. *A Van Leeuw J Microb* 2002; 82: 279–89.
 14. Boyle, J.R.; R.M. Robins-Browne and M.L.K. Tang (2006): Probiotic use in clinical practice: what are the risks? *American Society for Clinical Nutrition.*, 83:1256–1264.
 15. Vineetha, N; Vignesh, R, A and Sridhar, D (2015). Preparation, Standardization of Antibiotic Discs and Study of Resistance Pattern for First-Line Antibiotics in Isolates from Clinical Samples. *International Journal of Applied Research* 2015; 1(11): 624–631
 16. Daba H, Saidi S. Detection of bacteriocin-producing lactic acid bacteria from milk in various farms in north-east Algeria by a new procedure. *Agron Research.* 2015;13:907–18
 17. Jamalifar, H; Rahimi, HR; Samadi, N; Shahverdi, AR; Sharifian, Z; Hosseini, F; Eslahi, H and Fazeli, MR (2011). Antimicrobial activity of different *Lactobacillus* species against multidrug-resistant clinical isolates of *Pseudomonas aeruginosa*. *Iranian Journal of Microbiology.*3(1):21–25.
 18. Aly EA (2007) Characterization of a bacteriocin-like inhibitory substance produced by *Lactobacillus Plantarum* isolated from Egyptian homemade yogurt. *Science Asia* 33: 313–319.
 19. Atta HM, Refaat BM, El-Waseif AA (2009) Application of biotechnology for production, purification, and characterization of peptide antibiotic produced by probiotic *Lactobacillus Plantarum* NRRL B-227. *Global J Biotechnol Biochem* 4: 115–125.
 20. Tambekar DH, Bhutada SA (2010) An evaluation of the probiotic potential of *Lactobacillus* sp. from the milk of domestic animals commercially available probiotic preparations in prevention of enteric bacterial infections. *Recent Research in Science and Technology* 2: 82–88.

21. Raja, A., Gajalakshmi, P., and Imran M.M. (2009): Effect of *Lactobacillus lactis cremoris* isolated from Kefir against Food Spoilage Bacteria. *Am J Food Technol* 4: 201–209.
22. Hami, K. (2011): Antibacterial effects of probiotics isolated from yogurts against some common bacterial pathogens. *African Journal of Microbiology Research* Vol. 5(25): pp. 4363–4367.
23. Maarof, HA; Abdallah, M.I.M; Bazalou, M.S. and Abo-Samra, R.G. (2013). Effect of prob bacteria isolated from yogurts produced in Damietta City on some pathogenic bacterbacteriacnoticeof the 6th Animal Wealth Research Conf. in the Middle East & North Africa(2013) - pp. 38–51.
24. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant Gram-negative bacilli in North America. *Pharmacotherapy*. 2008;28:235–249.

Figures




Figure 1

A Characteristic colonies of *Lactobacillus* spp on BHIA.

B Microscopically appearance of *Lactobacilli* with Gram's stain.




Figure 2

Antimicrobial activity of (1) probiotic *Lactobacillus* strains supernatant, (2) BHIB (negative control), (3) Ampicillin, and (4) Gentamycin against different test pathogens **A** *Staphylococcus aureus*, **B** *Pseudomonas aeruginosa*, **C** *Escherichia coli*, and **D** *Klebsiella pneumoniae* by the disk diffusion method.